Trial Profile
A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects With Social Anxiety Disorder
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2006
Price :
$35
*
At a glance
- Drugs AV 608 (Primary)
- Indications Social phobia
- Focus Therapeutic Use
- Sponsors Avera Pharmaceuticals
- 28 Sep 2006 New trial record.